1081. Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • IDWeek-2018-Dalba-endocarditis-Final.pdf (1.1 MB)
  • Background: The management of endocarditis requires aggressive and prolonged antimicrobial treatment. Dalbavancin (DALBA) has demonstrated potent in vitro activity against gram-positive (GP) organisms commonly responsible for endocarditis and is being evaluated for treatment of complicated bacteremia and infective endocarditis.

    Methods: A total of 626 GP organisms were collected from patients with a diagnosis of bacterial endocarditis in the United States (USA; n=222) and Europe (EUR; n=404) from 2007 to 2017 via the SENTRY Antimicrobial Surveillance Program and were tested for susceptibility (S) against DALBA and comparators by CLSI broth microdilution.

    Results: The most common organisms were S. aureus (SA; 48.4%), E. faecalis (EF; 19.6%), and viridans group streptococci (VGS; 12.5%). DALBA and daptomycin (DAPTO) showed complete activity (100.0%S) against SA, but DALBA MICs were 4- to 8-fold lower (Table). Linezolid (LZD) and teicoplanin were also active against all SA; whereas vancomycin (VAN) and trimethoprim-sulfamethoxazole were active against 99.7% of isolates. Ceftaroline (CPT) exhibited potent activity against methicillin-susceptible SA (MSSA; MIC90, 0.25 mg/L; 100.0%S) and inhibited 78.4% of methicillin-resistant SA (MRSA) isolates at ≤1 mg/L. All EF isolates were S to ampicillin, DAPTO, and LZD, whereas 97.6% (120/123) of isolates were S to DALBA (MIC90, 0.06 mg/L) and 96.7%S to VAN (MIC90, 2 mg/L). Against EF, DALBA MIC values were 16-to 32-fold lower than DAPTO and VAN. All VGS and coagulase-negative staphylococcal (CoNS) isolates were S to DALBA, DAPTO, VAN, and LZD, and the highest CPT MICs were 0.5 mg/L for VGS and 4 mg/L for CoNS (93.5% inhibited at ≤1 mg/L). Against E. faecium (EFM), 65.7% of isolates were inhibited at ≤0.25 mg/L of DALBA and 62.9% were VAN-S. All EFM were S to DAPTO and LNZ. β-hemolytic streptococci (BHS) was S to most antimicrobial agents, and only 66.7% of S. pneumoniae (SPN) isolates were PEN-S at ≤0.06 mg/L.

    Conclusion: DALBA exhibited potent in vitro activity against a large collection of GP isolates recovered from patients with endocarditis in US and EUR medical centers. These results support further investigations to determine the role of DALBA in the treatment of infective endocarditis.

    Helio S. Sader, MD, PhD1, Rodrigo E. Mendes, Ph.D.2, Michael A. Pfaller, M.D.2 and Robert K. Flamm, PhD3, (1)JMI Laboratories, North Liberty, IA, (2)JMI Laboratories, Inc., North Liberty, IA, (3)United States Committee on Antimicrobial Susceptibility Testing, Silverton, OR

    Disclosures:

    H. S. Sader, Allergan: Research Contractor , Research support .

    R. E. Mendes, Allergan: Research Contractor , Research support .

    M. A. Pfaller, Allergan: Research Contractor , Research support .

    R. K. Flamm, Allergan: Research Contractor , Research support .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.